Benzinga··Vandana SinghGSK Bets on China's Hepatitis B Boom With Sino Biopharmaceutical Partnership
GSK partners with Sino Biopharmaceutical to commercialize hepatitis B drug bepirovirsen in China under priority regulatory review, while completing £2 billion share buyback.
GSKIONSstrategic partnershipshare buyback